|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide and a major cause of chronic kidney disease and failure.
|
31402200 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is the leading primary GN worldwide.
|
31444275 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide.
|
31464185 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide.
|
31542837 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is one of the most common chronic glomerulonephritis.
|
31551340 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is a mesangial proliferative glomerulonephritis which often shows proteinuria, an indicator for podocyte damage.
|
31600491 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) involves mesangial matrix expansion, but the proteomic composition of this matrix is unknown.
|
31726998 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is primarily resulted of qualitative abnormality of IgA.
|
31815288 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is one of the most diffuse glomerulonephrites worldwide, and many issues still remain regarding our understanding of its pathogenesis.
|
31838587 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A group of 27 patients with IgA nephropathy (IgAN) and persistent microhematuria, and another group of 20 healthy subjects without known renal diseases were selected as control groups.
|
9734616 |
1998 |
|
IGA Glomerulonephritis
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
A representative animal model of IgA nephropathy (IgAN) is lacking.
|
28391340 |
2017 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aberrant galactose-deficient IgA1 molecules (Gd-IgA1) are important causal factors in IgA nephropathy (IgAN); however, the detection of Gd-IgA1 in IgAN is complicated and instable.
|
31574506 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adjusted transplant rates were highest for patients with IgA nephropathy (IgAN) (referent) and lower for all other groups: focal segmental glomerulosclerosis (HR, 0.80; 95% CI, 0.77-0.82), membranous nephropathy (HR, 0.88; 95% CI, 0.83-0.93), membranoproliferative GN (HR, 0.84; 95% CI, 0.76-0.92), lupus nephritis (HR, 0.69; 95% CI, 0.66-0.71), vasculitis (HR, 0.66; 95% CI, 0.61-0.70), DN (HR, 0.50; 95% CI, 0.47-0.52), ADPKD (HR, 0.85; 95% CI, 0.82-0.88).
|
28207635 |
2017 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although IgA nephropathy (IgAN) is the most common glomerulonephritis in the world, there is no validated tool to predict disease progression.
|
30980653 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among 1070 patients, 429 had IgA nephropathy (IgAN), 641 had non-IgAN.
|
30885171 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among 42 patients, podocin was normally expressed in glomeruli in purpura nephritis, IgA nephropathy (IgAN), and minimal-change disease (MCD), while it was either decreased or absent in most subjects with focal segmental glomerulosclerosis (FSGS).
|
14633131 |
2003 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among the 32,131 patients with GN studied, patients with IgA nephropathy (IgAN) had the lowest mortality rates and patients with IgAN or vasculitis had the lowest allograft failure rates.
|
27432742 |
2017 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among the different pathological types of PNS, IgA nephropathy (IgAN) and membranous nephropathy (MN) were associated with significantly increased frequencies of the 4G/4G and 4G/5G genotypes, as well as of the 4G allele.
|
24435552 |
2014 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) as the commonly used renin-angiotensin aldosterone system inhibitor are widely used in patients with IgA nephropathy (IgAN), but the effect is controversy.
|
31700813 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Association between pulmonary disease and IgA nephropathy (IgAN) has been previously reported.
|
31217208 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because variance in the disease incidence and predisposing genes of IgAN has been detected among different ethnicities, the ethnicity factor should be considered in IgAN biomarker discovery.
|
30547763 |
2018 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both ABO blood group antigens and pathogenic immunoglobulin A1 (IgA1) in patients with IgA nephropathy (IgAN) are influenced by modifications of N-acetylgalactosamine and galactose.
|
31603230 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Characterization of the IgAN1 gene linked to IgAN in some Italian and American multiplex families has remained elusive.
|
17495433 |
2007 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Corticosteroids can be used to treat IgA nephropathy (IgAN).
|
31408863 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Focal segmental glomerular sclerotic lesions in IgA nephropathy (IgAN), considered for years a chronic histologic feature related to proteinuria in remnant nephrons without any active role in the pathogenesis and progression of glomerular damage of IgAN, have been recently reconsidered.
|
31773265 |
2019 |